Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 16% of the global population, and its progression to steatohepatitis (MASH) increases the risk of cirrhosis and hepatocellular carcinoma. Long non-coding RNAs (lncRNAs) have been implicated in MASLD/MASH, but their precise contributions to disease pathology remain poorly understood. We analyzed public liver transcriptome datasets (GSE126848, GSE130970, GSE135251) and a single-nucleus RNA-seq dataset (GSE202379), validated candidates by qRT-PCR in liver samples from MASLD patients and non-MASLD controls, and performed siRNA-mediated knockdown in HepG2 cells treated with FFA/LPS. We identified 14 overlapping DElncRNAs in GSE126848 and GSE130970 datasets, and functional annotation of the overlapping DEmRNAs showed enrichment of lipid storage and inflammatory pathways. Six lncRNAs were replicated in an independent cohort (GSE135251), and three of them (AJ009632.2, LINC00885, and LINC02749) showed sustained upregulation across disease stages and were detectable, albeit sparsely, in both parenchymal and non-parenchymal nuclei. Although only AJ009632.2 and LINC00885 were elevated in our clinical cohort, all three were induced in FFA/LPS-treated HepG2 cells, with AJ009632.2 showing the largest increase. Silencing AJ009632.2 attenuated FFA/LPS-induced lipid accumulation and the expression of lipid metabolism and inflammatory genes, accompanied by reduced STAT3 phosphorylation. These findings associate AJ009632.2 with MASLD/MASH pathogenesis and support further mechanistic investigation.
No takes yet. Share an insight, caveat, or question.
Ngowi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: